SUMMARY
INTRODUCTION
It is estimated that gastric cancer (GC), one of the most common cancers worldwide, has an incidence of 640,000 cases for men and 350,000 cases for women and caused death of about 464,000 men and 273,000 women in 2011 [1] . Though both diagnosis and treatment methods have been improved in recent years, the prognosis of advanced gastric cancer is still poor mainly due to metastasis, with a median overall survival less than 1 year [2, 3] . Most of GC patients are diagnosed as advanced, inoperable, or metastatic stage when admitted, and the only solutions left for these patients is to maintain quality of life and prolong survival [4, 5] . Thus early diagnosis for GC is always important and new diagnostic biomarkers are still needed [6] . Currently, several potential biomarkers in the diagnosis of GC have been already reported, such as epidermal growth factor [7] , human epidermal growth factor 2 (HER2) [8] , and vascular endothelial growth factor (VEGF) [9] . Recently, the role of the Nin one binding protein (NOB1) gene in cancer development has attracted scholars' eyes. It is reported that NOB1 is up-regulated in several cancers [10, 11] and contributes to cancer development such as proliferation [12] , apoptosis, migration and metastasis [11] of cancer cells. However, few studies focused on role of the NOB1 gene in GC cells and patients. In the present study, we demonstrated the relationship of expression of NOB1 mRNA with the prognosis of GC patients and its possible relationship with VEGF. This study might provide more clinical evidence for NOB1 in GC and give a new target for diagnosis and treatment for GC patients.
MATERIALS AND METHODS

Patient samples and data collection
The GC tumor tissues and paired adjacent normal gastric tissues were collected from 65 patients who underwent primary gastric resection surgery in our hospital from January 2009 to July 2011. All tissues were fresh frozen until used. All patients were diagnosed and confirmed by pathological study and no patients received chemotherapy or radiotherapy before the surgery. Demographic data such as age, gender, and family cancer history were collected. Clinical data including tumor diameter, pathological type, differentiation, clinical stage by tumor node metastasis (TNM) staging, lymphatic metastasis, and distant metastasis were collected. Informed consents were obtained from all patients. The present study was approved by the ethics committee of Renji hospital.
Real time PCR
Expression of NOB1 and VEGF was determined using Real time PCR as described elsewhere [13] . Briefly, total RNA was extracted from GC and normal tissues by Trizol reagent (Tiangen Biotech, Beijing, China) following the manufacturer's instructions. The PrimeScript TM one step RT-PCR kit (TAKARA, Dalian, China) was used to convert RNA into cDNA. PCR reactions were performed using Green PCR Master Mix (TAKARA, Dalian, China) in an ABI7500 System (Applied Biosystems, Foster City, CA, USA). The primer sequences used in this study was as follows: NOB1, forward 5'-ACA TAC CAG TTG GAA GCA GAG-3' and reverse 5'-CAG GTT CTC AGG CTC ACA AG-3'; VEGF, forward 5'-AGG GCA GAA TCA TCA CGA AG-3' and reverse 5'-CAC ACA GGA TGG CTT GAA GA-3'; GAPDH, forward 5'-GAA GGT GAA GGT CGG AGTC-3' and reverse 5'-GAA GAT GGT GAT GGG ATT TC-3'. The NOB1 and VEGF mRNA levels were normalized to that of GAPDH. Relative mRNA levels were calculated by the 2 -ΔΔCq method.
Statistical analysis
The measurement data was expressed as mean ± SD.
Comparison between two groups of continuous data was performed using the Student's t-test. Chi square test was used to compare the categorical variables. Pearson's correlation analysis was performed to analyze the correlation of NOB1 and VEGF. For 5-year survival analysis, length of survival was calculated from the date of hospital discharge to the date of death and KaplanMeier curve was performed with the log-rank test. For logistic analysis, univariate analysis was performed using χ 2 test and Student's t-test and the significant factors in univariate analysis were chosen to conduct logistic multivariate regression using a logistic regression model by stepwise method. Values were considered to be statistically significant when p was less than 0.05. All calculations were made using SPSS 18.0.
RESULTS
NOB1 was up-regulated in GC tissues and was positively correlated with the expression of VEGF
First, the expression of NOB1 and VEGF in all tissue samples was determined using real time PCR. As shown in Figure 1A , both expression of NOB1 and VEGF was significantly higher in tumor tissues than that of the normal tissues, p < 0.05, indicating that expression of NOB1 and VEGF was up-regulated in GC patients. To further study the relationship of NOB1 and VEGF in GC patients, Pearson's correlation analysis was performed. Results showed that the mRNA expression of NOB1 was positively correlated with mRNA expression of VEGF in GC tissues, p < 0.05 ( Figure 1B) .
Relationship of the expression of NOB1 with clinical outcomes of GC patients
The present study included GC tissues from a total of 65 patients, with a mean age of 59.77 ± 4.71 years, male: female 40: 25, and mean tumor diameter 4.48 ± 2.44 cm. Among all patients, tumor was located on gastric fundus cardia in 31 samples, on the body of the stomach in 13 patients, and on gastric antrum in 21 patients. Thirty-four patients were diagnosed as TNM stage I or II, and 31 patients with TNM III or IV. Results of tumor differentiation showed that 19 samples were well differentiated, 21 samples moderately differentiated, and 25 samples poorly differentiated. Thirtysix samples had lymphatic metastasis and 37 samples had distant metastasis. To further investigate the relationship of NOB1 and GC patients, patients were divided into low NOB1 expression and high NOB1 expression groups according to the median value of NOB1 expression. As shown in Table  1 , a significant difference was observed in TNM stage, tumor differentiation, and metastasis between the low and high expression groups, p < 0.05. However, no significant difference was observed in age, gender, family cancer history, tumor location, and diameter. These results indicated that expression of NOB1 might be associated with TNM stage, tumor differentiation, and tumor metastasis of GC patients.
Relationship of NOB1 with mortality of GC patients
Lastly, we analyzed the relationship of NOB1 with 5-year mortality of GC patients using Kaplan-Meier curves. Results showed that patients with higher expression of NOB1 or VEGF had lower survival time ( Figure  2 ). Univariate analysis showed that TNM stage, tumor differentiation, lymphatic metastasis, distant metastasis, and expression of NOB1 and VEGF were all significantly different in survival and deceased patients, p < 0.05 (Table 2) . Meanwhile, logistic analysis showed that NOB1 was an independent risk factor for 5-year mortality of GC patients, as well as lymphatic metastasis and distant metastasis (Table 3) . 
DISCUSSION
Despite advances in development of surgical therapy for gastric cancer (GC) and improvement in early diagnosis, the prognosis of metastatic GC is still poor, with a 5-year survival rate about only 3.1% in advanced GC patients [14] . Since most GC patients are diagnosed when the tumor is at an unresectable stage, early diagnosis of GC is crucial for treatment [15] . Studies showed that the NOB1 gene was associated with tumor development in various cancers such as ovarian cancer [16] , laryngeal cancer [17] , lung cancer [18] , colorectal cancer [19] , and gastric cancer [20] and could be a potential biomarker in predicting prognosis of lung cancer outcomes [18, 21] . There is also a study demonstrating NOB1 was up-regulated in gastric cancer tissues [22] . However more evidence is still needed to illuminate the relationship of NOB1 with prognosis of GC patients. In the present study, for the first time, we demonstrated that NOB1 was correlated with differentiation, stage, and metastasis of GC, as well as expression of VEGF in GC patients. Meanwhile NOB1 was also an independent risk factor for 5-year mortality of GC patients. First, we confirmed that both NOB1 and VEGF mRNA was up-regulated in GC patients. NOB1 was found to be up-regulated in several cancers. Liu et al. found that NOB1 mRNA in non-small-cell lung cancer cells was higher than in human lung cells [23] . Zhang et al. showed that NOB1 was elevated in prostate cancer tissues compared to the adjacent normal tissues [24] . Zhou et al. demonstrated that NOB1 was over expressed in patients with gastric cancer [22] . The up-regulation of VEGF in many cancers and its clinical significance has been also well demonstrated in many cancers studied, including gastric cancer [25, 26] . All these results are consistent with our findings. Meanwhile, we also firstly showed that expression of NOB1 was positively correlated with the expression of VEGF. We then studied the correlation of NOB1 and clinical outcomes of GC patients and results showed that NOB1 was correlated with differentiation, stage, and metastasis of GC. Liu et al. found that expression of NOB1 was highly expressed in non-small-cell lung cancer cells and tissues, and was significantly associated with the TNM clinical stage, lymph node metastasis, and differentiation of the cancer [21] . Ji et al. found that miR-326 could inhibit gastric cancer cell growth by down regulating NOB1 [20] . Zhou et al. demonstrated that NOB1 was over expressed in GC patients; however, they found expression of NOB1 had no direct relationship with the patient's age, gender, tumor differentiation or infiltration degree, lymphatic metastasis, distant metastasis or pTNM periodization, but was directly related to the size of the tumor [22] . In our study, the results showed different conclusions compared with Zhou's study. These differences might be due to different clinical samples which needed more studies to further confirm. In addition, we also first demonstrated that NOB1 was correlated with the 5-year survival of GC patients, as well as lymphatic metastasis and distant metastasis. The present study also had some limitations. First, considering the quantitative results, we did not use immunohistochemistry methods to evaluate the level of NOB1 but only used real time PCR. Second, the sample size we used was still small and the sources were single. Last, in vitro studies are still needed to give deeper insights into the molecular mechanisms for NOB1 in GC cells. All these will be further studied in further research.
CONCLUSION
We conducted a clinical study to investigate the relationship of NOB1 with the prognosis of gastric cancer. Results showed that NOB1 was correlated with differentiation, stage, and metastasis of GC, as well as expression of VEGF in GC patients. Meanwhile NOB1 was also an independent risk factor for 5-year mortality of GC patients. This study might provide more clinical evidence for NOB1 in GC and give a new target for diagnosis and treatment for GC patients.
